Capricor Therapeutics Analyst Ratings
Capricor Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 172.31% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 03/16/2023 | 172.31% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 10/26/2022 | 126.93% | Ladenburg Thalmann | → $15 | Initiates Coverage On | → Buy |
| 01/31/2022 | 172.31% | HC Wainwright & Co. | $14 → $18 | Maintains | Buy |
| 10/11/2021 | 111.8% | HC Wainwright & Co. | $9 → $14 | Maintains | Buy |
| 07/15/2019 | 87.59% | HC Wainwright & Co. | $3.5 → $12.4 | Maintains | Buy |
| 12/31/2018 | -47.05% | HC Wainwright & Co. | $8.6 → $3.5 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/15/2023 | 172.31% | HC Wainwright & Co. | → 18 美元 | 重申 | 购买 → 购买 |
| 03/16/2023 | 172.31% | HC Wainwright & Co. | → 18 美元 | 重申 | → 购买 |
| 2022 年 10 月 26 日 | 126.93% | 拉登堡塔尔曼 | → 15 美元 | 启动覆盖开启 | → 购买 |
| 01/31/2022 | 172.31% | HC Wainwright & Co. | 14 美元 → 18 美元 | 维护 | 购买 |
| 2021 年 11 月 10 日 | 111.8% | HC Wainwright & Co. | 9 美元 → 14 美元 | 维护 | 购买 |
| 07/15/2019 | 87.59% | HC Wainwright & Co. | 3.5 美元 → 12.4 美元 | 维护 | 购买 |
| 12/31/2018 | -47.05% | HC Wainwright & Co. | 8.6 美元 → 3.5 美元 | 维护 | 购买 |
What is the target price for Capricor Therapeutics (CAPR)?
Capricor Therapeutics（CAPR）的目标价格是多少？
The latest price target for Capricor Therapeutics (NASDAQ: CAPR) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $18.00 expecting CAPR to rise to within 12 months (a possible 172.31% upside). 3 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年8月15日公布了Capricor Therapeutics（纳斯达克股票代码：CAPR）的最新目标股价。这家分析公司将目标股价定为18.00美元，预计CAPR将在12个月内升至12个月内（可能上涨172.31％）。去年有3家分析公司公布了评级。
What is the most recent analyst rating for Capricor Therapeutics (CAPR)?
分析师对Capricor Therapeutics（CAPR）的最新评级是多少？
The latest analyst rating for Capricor Therapeutics (NASDAQ: CAPR) was provided by HC Wainwright & Co., and Capricor Therapeutics reiterated their buy rating.
Capricor Therapeutics（纳斯达克股票代码：CAPR）的最新分析师评级由HC Wainwright & Co. 提供，Capricor Therapeutics重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Capricor Therapeutics (CAPR)?
Capricor Therapeutics（CAPR）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Capricor Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Capricor Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Capricor Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Capricor Therapeutics的最后一次评级是在2023年8月15日提交的，因此你应该预计下一个评级将在2024年8月15日左右公布。
Is the Analyst Rating Capricor Therapeutics (CAPR) correct?
分析师对 Capricor Therapeutics (CAPR) 的评级正确吗？
While ratings are subjective and will change, the latest Capricor Therapeutics (CAPR) rating was a reiterated with a price target of $0.00 to $18.00. The current price Capricor Therapeutics (CAPR) is trading at is $6.61, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Capricor Therapeutics（CAPR）评级得到了重申，目标股价为0.00美元至18.00美元。Capricor Therapeutics（CAPR）目前的交易价格为6.61美元，在分析师的预测区间内。